FDA Inspection of Novartis Lab Raises More Questions About Data Falsification

Drug Industry Daily
A A
A Form 483 issued following an FDA inspection of Novartis subsidiary AveXis’ control testing laboratory — currently the focus of a data manipulation investigation by the agency — is raising concerns about the firm’s own investigation and when it knew about the data discrepancies.

To View This Article:

Login

Subscribe To Drug Industry Daily